LLY

914.51

+0.93%↑

UNH

577.15

-0.55%↓

NVO

134.78

+2.03%↑

JNJ

164.87

-0.88%↓

ABBV

193.46

+0.25%↑

LLY

914.51

+0.93%↑

UNH

577.15

-0.55%↓

NVO

134.78

+2.03%↑

JNJ

164.87

-0.88%↓

ABBV

193.46

+0.25%↑

LLY

914.51

+0.93%↑

UNH

577.15

-0.55%↓

NVO

134.78

+2.03%↑

JNJ

164.87

-0.88%↓

ABBV

193.46

+0.25%↑

LLY

914.51

+0.93%↑

UNH

577.15

-0.55%↓

NVO

134.78

+2.03%↑

JNJ

164.87

-0.88%↓

ABBV

193.46

+0.25%↑

LLY

914.51

+0.93%↑

UNH

577.15

-0.55%↓

NVO

134.78

+2.03%↑

JNJ

164.87

-0.88%↓

ABBV

193.46

+0.25%↑

Home・Aktien・Amarin Corp PLC ADR

Amarin Corp PLC ADR

Geschlossen

0.59 1.72

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.58

Max

0.6

Schlüsselkennzahlen
By Trading Economics
Einkommen	11M 1.5M
Verkäufe	11M 67M
EPS	0.01
Gewinnspanne	2.252
EBITDA	13M 237K

Empfehlungen
By TipRanks
Empfehlungen	Sell
12-Monats-Prognose	+66.67 upside

Dividenden
By Dow Jones
Nächstes Ergebnis	30. Okt. 2024

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-11M 246M
Vorheriger Eröffnungskurs	-1.13
Vorheriger Schlusskurs	0.59

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

0.586 / 0.6035 Unterstützung & Widerstand

Amarin Corp PLC ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

19. Sept. 2024, 23:50 UTC

Heiße Aktien

Stocks to Watch: Nike, FedEx, Alliance Entertainment Holding, Arq

19. Sept. 2024, 20:59 UTC

Ergebnisse

FedEx Cuts Full-Year Outlook After Posting Lower Profit, Revenue in 1Q -- Update

19. Sept. 2024, 20:41 UTC

Top News

Nike CEO John Donahoe to Retire

19. Sept. 2024, 20:40 UTC

Ergebnisse

FedEx Cuts Full-Year Outlook After Posting Lower Profit, Revenue in 1Q

19. Sept. 2024, 23:24 UTC

Market Talk

Sims U.S. Business Shines, But Asia Headwinds Remain -- Market Talk

19. Sept. 2024, 23:01 UTC

Top News

U.K. Consumers Turn Notably Gloomier, Survey Says

19. Sept. 2024, 22:21 UTC

Market Talk

Ergebnisse

FedEx Warns of Continued, Worsening Headwinds in 2Q -- Market Talk

19. Sept. 2024, 22:17 UTC

Top News

Why Fed Rate Cuts Are Hurting Treasury Bonds -- Barrons.com

19. Sept. 2024, 22:13 UTC

Market Talk

Ergebnisse

FedEx Counts on Price Hikes to Help Hurting Top and Bottom Lines -- Market Talk

19. Sept. 2024, 22:13 UTC

Market Talk

Ergebnisse

Global Equities Roundup: Market Talk

19. Sept. 2024, 22:06 UTC

Ergebnisse

FedEx Stock Is Down. Earnings Show Why The Fed Cut Rates. -- Barrons.com

19. Sept. 2024, 21:46 UTC

Top News

Ergebnisse

FedEx Cuts Full-Year Outlook After Posting Lower Profit, Revenue -- Update

19. Sept. 2024, 21:06 UTC

Ergebnisse

FedEx Stock Slumps. It Wasn't Just the Earnings That Were Bad. -- Barrons.com

19. Sept. 2024, 20:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

19. Sept. 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

19. Sept. 2024, 20:50 UTC

Market Talk

Ergebnisse

Auto & Transport Roundup: Market Talk

19. Sept. 2024, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

19. Sept. 2024, 20:42 UTC

Ergebnisse

FedEx Stock Skids, Set To Snap Support As Q1 Results Disappoint -- IBD

19. Sept. 2024, 20:39 UTC

Top News

Dow, S&P 500 Hit Records After Rate Cut -- WSJ

19. Sept. 2024, 20:12 UTC

Ergebnisse

FedEx Unable to Provide FY25 EPS or Effective Tax Rate Outlook on GAAP Basis >FDX

19. Sept. 2024, 20:12 UTC

Ergebnisse

FedEx Cash On-Hand as of Aug 31 Was $5.9 B >FDX

19. Sept. 2024, 20:11 UTC

Ergebnisse

FedEx Stock Slumps. It Wasn't Just the Earnings That Were Bad. -- Barrons.com

19. Sept. 2024, 20:11 UTC

Ergebnisse

FedEx: 'Committed to Our Plan to Return $3.8 B to Stockholders This Fiscal Yr' >FDX

19. Sept. 2024, 20:11 UTC

Ergebnisse

FedEx Expects Recent Pricing Actions to Help Offset Weaker-Than-Expected Demand Trends >FDX

19. Sept. 2024, 20:10 UTC

Top News

Dow Crosses 42000, Hits Record in Post-Fed Rally -- WSJ

19. Sept. 2024, 20:10 UTC

Ergebnisse

FedEx Reaffirms FY25 Capital Spending of $5.2 B >FDX

19. Sept. 2024, 20:10 UTC

Ergebnisse

FedEx Reaffirms Permanent Cost Reductions From DRIVE Transformation Program of $2.2 B >FDX

19. Sept. 2024, 20:10 UTC

Ergebnisse

FedEx Had Previously Forecast of Low-To-Mid Single Digit Percentage Increase in Rev for FY25>FDX

19. Sept. 2024, 20:09 UTC

Ergebnisse

FedEx Sees Low Single-Digit Percentage Rev Growth Rate Yr Over Yr for FY25>FDX

19. Sept. 2024, 20:09 UTC

Ergebnisse

FedEx Sees FY25 EPS $20 to $21 After Also Excluding Costs Related to Business Optimization Initiatives >FDX

Peer-Vergleich

Kursveränderung

Amarin Corp PLC ADR Prognose

Kursziel

By TipRanks

66.67% Vorteil

12-Monats-Prognose

Durchschnitt 1 USD 66.67%

Hoch 1 USD

Tief 1 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Amarin Corp PLC ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Sell

2 ratings

Buy

Halten

Sell

Basierend auf 2 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Amarin Corp PLC ADR – Dist abgegeben haben.

Technischer Score

By Trading Central

0.586 / 0.6035Unterstützung & Widerstand

Bullish events outweigh bearish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Amarin Corp PLC ADR

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.